WT1 TCR-transduced T-cell therapy (Takara Bio)

N/A

Report date: 2026/02/26 20:00:22

Base Information

Drug NameWT1 TCR-transduced T-cell therapy (Takara Bio)

Drug Alias NameWT1 antigen-specific TCR-gene-transduced autologous lymphocytes-Takara BioWT1 antigen-specific RetroNectin TCR gene therapy-Takara Bio

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy

Mechanisms of ActionImmunostimulantsGene transferenceWilms' Tumour 1 modulators

TargetsWilms' Tumour 1

Therapy Area/IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesTakara Bio Inc

China Registration ClassN/A

Active CompaniesTakara Bio Inc

Inactive CompaniesN/A

Active IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, Acute

Inactive IndicationsN/A

ATC CodeN/A